Comparing the current results to its competitors, Veru Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.02 %, recorded in the same quarter.
Veru Inc , slower than the average decrease reported by the company's competitors of -64.43 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -64.43 %
July 29, 2024
Veru Inc. Engages Investors at BTIG Virtual Biotechnology Conference and Makes Progress with Enobosarm Clinical Trials for High-Quality Weight Loss Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company headquartered in Miami, Florida, is at the forefront of innovation in the healthcare sector. On July 29, 2024, the company announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5, 2024. This event will provide an opportunity for Veru to engage in one-on-one meetings with investors, highlighting its commitment to transparency and communication with stakeholders as it continues to develop cutting-edge medicinesFocused on preserving muscle whil...
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Sources:
Veru Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Veru Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
